<DOC>
	<DOCNO>NCT00939003</DOCNO>
	<brief_summary>This study evaluate well adalimumab work short long term patient axial spondyloarthritis diagnose either ankylose spondylitis psoriatic arthritis .</brief_summary>
	<brief_title>Study Adalimumab Patients With Axial Spondyloarthritis</brief_title>
	<detailed_description>This Phase 3 , placebo-controlled , double-blind randomize study open-label phase design evaluate efficacy safety adalimumab 40 mg administer every week adult patient active axial spondyloarthritis ( SpA ) diagnose ankylose spondylitis , psoriasis , psoriatic arthritis inadequate response intolerance one nonsteroidal anti-inflammatory drug ( NSAIDs ) contraindication NSAIDs . Participants receive adalimumab placebo 12 week double-blind phase study . Following double-blind phase , remain participant enter open-label phase study receive open-label adalimumab 144 week . Efficacy endpoint include Assessment Spondyloarthritis International Society ( ASAS ) response criterion patient SpA . These response criterion use determine participant responder . ASAS response involve evaluation follow 4 domain : participant 's global assessment disease activity , pain , function , inflammation . The patient 's global assessment disease activity score assess use 100 millimeter ( mm ) visual analog scale ( VAS ; 0 disease activity 100 severe disease activity ) . Pain represent total back pain score assess use 100 mm VAS ( 0 pain 100 severe pain ) . Function score represent Bath Ankylosing Spondylitis ( AS ) Functional Index ( BASFI ) 100 mm VAS score ( average ability perform 10 activity , score 0 easy 100 impossible ) . Inflammation determine use morning stiffness overall level score ( 0 none 10 severe ) duration score ( 0 0 hour 10 ≥ 2 hour ) Bath AS Disease Activity Index ( BASDAI ) ( mean item # 5 # 6 score ) . In addition , BASDAI use efficacy endpoint . The BASDAI use participant ass his/her disease activity . Using VAS scale , participant answer 6 question pertain symptom experience past week . For 5 question ( level : fatigue/tiredness ; AS neck , back , hip pain ; pain/swelling ; discomfort area tender touch pressure ; morning stiffness ) , response scale 0 ( none ) 10 ( severe ) . For 1 question ( duration morning stiffness ) , response scale 0 ( 0 hour ) 10 ( ≥ 2 hour ) .</detailed_description>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult patient inadequate response &gt; /= 1 nonsteroidal antiinflammatory drug ( NSAIDs ) Chronic back pain onset &lt; 45 year age Magnetic resonance imaging ( MRI ) indicate active sacroiliitis positive human leukocyte antigenB27 ( HLAB27 ) blood test addition meeting spondyloarthritis clinical criterion Negative purify protein derivative ( PPD ) test chest xray perform Baseline visit must negative Ability administer subcutaneous injection General good health otherwise Prior antitumor necrosis factor ( TNF ) therapy Psoriasis psoriatic arthritis Fulfillment modify New York criterion ankylose spondylitis Recent infection require treatment Significant medical event condition may put patient risk participation Females pregnant breastfeeding consider become pregnant study History cancer , except successfully treat skin cancer Recent history drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>